Company profile
Sienna Biopharmaceuticals, Inc.
OTC: SNNAQ · Healthcare · Biotechnology
#1161 of 1,418 Healthcare companies by revenue
EA Score
——FH —DQ —GM —SS 28
v0.1 · 5/100 weight · pillars only
↑ listing tenure, balance-sheet leverage · ↓ market scale, return on equity
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$73.3M
Employees
13
as of 2026-08-30
Market cap
$3.1k
as of 2026-08-30
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02018
Net income-$73.3M-$73.3M2018
Operating income-$76.5M-$76.5M2018
Total assets$107.3M$107.3M2018
Liabilities$80.7M$80.7M2018
Equity$159.4M$159.4M2018
Revenue trend
FY2015 – FY2018 · USD
FY15
FY16
FY17
FY18
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Sienna Biopharmaceuticals, Inc.’s revenue?
Sienna Biopharmaceuticals, Inc. booked $0 in FY2018 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Xeno Transplants Corporation——Claritas Pharmaceuticals, Inc.——Rapid Therapeutic Science Laboratories, Inc.——Global Hemp Group Inc.——OncoVista Innovative Therapies, Inc.——Cotinga Pharmaceuticals Inc.——Neighbors
Los Angeles →Key facts
CEODavid E. I. Pyott
SectorHealthcare
IndustryBiotechnology
HeadquartersWestlake Village, CA
ExchangeOTC: SNNAQ
Employees13
IPO date2017-07-27
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.